<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "7: materially from current expectations which", fill: "#cd9575"},
{source: "7: materially from current expectations which", target: "7: product candidate development efforts", fill: "#cd9575"},
{source: "7: product candidate development efforts", target: "7: clinical testing", fill: "#cd9575"},
{source: "7: clinical testing", target: "7: increased regulation by", fill: "#cd9575"},
{source: "7: increased regulation by", target: "7: introduction", fill: "#cd9575"},
{source: "7: introduction", target: "7: competitive products", fill: "#cd9575"},
{source: "7: competitive products", target: "7: impairment", fill: "#cd9575"},
{source: "7: impairment", target: "7: license patent", fill: "#cd9575"},
{source: "7: license patent", target: "7: proprietary rights", fill: "#cd9575"},
{source: "7: proprietary rights", target: "7: market acceptance", fill: "#cd9575"},
{source: "7: market acceptance", target: "7: future collaborative agreements", fill: "#cd9575"},
{source: "7: future collaborative agreements", target: "7: successfully", fill: "#cd9575"},
{source: "7: successfully", target: "7: drug development strategy", fill: "#cd9575"},
{source: "7: materially from current expectations which", target: "12: incur losses", fill: "#0067a5"},
{source: "12: incur losses", target: "12: development", fill: "#0067a5"},
{source: "12: incur losses", target: "13: funds will", fill: "#ffbcd9"},
{source: "13: funds will", target: "13: research expenses", fill: "#ffbcd9"},
{source: "13: research expenses", target: "13: commercialization", fill: "#ffbcd9"},
{source: "13: commercialization", target: "13: product candidates", fill: "#ffbcd9"},
{source: "13: funds will", target: "19: significant", fill: "#00ced1"},
{source: "19: significant", target: "19: development", fill: "#00ced1"},
{source: "19: development", target: "19: regulatory", fill: "#00ced1"},
{source: "19: regulatory", target: "19: administrative", fill: "#00ced1"},
{source: "19: administrative", target: "19: generate revenue", fill: "#00ced1"},
{source: "19: generate revenue", target: "19: incur losses", fill: "#00ced1"},
{source: "19: incur losses", target: "19: next several years", fill: "#00ced1"},
{source: "19: next several years", target: "19: losses will increase as", fill: "#00ced1"},
{source: "19: losses will increase as", target: "19: development activities", fill: "#00ced1"},
{source: "19: development activities", target: "19: incur significant expenses", fill: "#00ced1"},
{source: "19: incur significant expenses", target: "19: clinical trials", fill: "#00ced1"},
{source: "19: significant", target: "35: Chrysalin ", fill: "#bb6528"},
{source: "35: Chrysalin ", target: "35: product candidates", fill: "#bb6528"},
{source: "35: product candidates", target: "35: fundamental inefficacy issues", fill: "#bb6528"},
{source: "35: fundamental inefficacy issues", target: "35: clinical trials", fill: "#bb6528"},
{source: "35: clinical trials", target: "35: could impact", fill: "#bb6528"},
{source: "35: could impact", target: "35: development path", fill: "#bb6528"},
{source: "35: Chrysalin ", target: "START_HERE", fill: "#bb6528"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial_management_system">Clinical trial management system</a></td>
      <td>A Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to manage clinical trials in clinical research. The system maintains and manages planning, performing and reporting functions, along with participant contact information, tracking deadlines and milestones.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/AC_Mobil_34_Chrysalin">AC Mobil 34 Chrysalin</a></td>
      <td>The AC Mobil 34 Chrysalin is a two-seat light aircraft produced in France in kitplane form. The aircraft was designed to comply with the Fédération Aéronautique Internationale microlight rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/AC_Mobil_34">AC Mobil 34</a></td>
      <td>AC Mobil 34 is a small French aircraft manufacturer based in Saint-Florentin.  The firm produces a light aircraft in kitplane form.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ORTHOLOGIC CORP      Item 1A Risk Factors     Risks          OrthoLogic may from time to time make written or oral forward-looking     statements,  including  statements  contained  in our <font color="blue">filings with</font> the     <font color="blue">Securities and Exchange Commission </font>and our reports to <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The safe     harbor for forward-looking statements contained in the Private Securities     <font color="blue">Litigation </font>Reform Act of 1995 protects companies from <font color="blue">liability</font> for their     forward looking statements if they <font color="blue">comply with</font> the <font color="blue">requirements</font> of that Act</td>
    </tr>
    <tr>
      <td><font color="blue">This <font color="blue">Annual Report </font></font>on Form 10-K contains forward-looking statements made     pursuant to that <font color="blue">safe harbor</font></td>
    </tr>
    <tr>
      <td>These forward-looking statements relate to     <font color="blue">future events</font> or to our <font color="blue">future financial performance</font>, and <font color="blue">involve known</font> and     <font color="blue">unknown risks</font>, <font color="blue">uncertainties</font> and                                         13       _________________________________________________________________    [46]Table of <font color="blue">Contents       </font>other  factors  that may cause our actual results, levels of activity,     performance, or <font color="blue">achievements</font> to be <font color="blue">materially</font> <font color="blue">different</font> from any future     results,  levels of activity, performance or <font color="blue">achievements</font> expressed or     implied by these forward-looking statements</td>
    </tr>
    <tr>
      <td>In some cases, you can identify     forward-looking statements by the use of words such as “may,” “could,”     “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,”     “predict,” “potential,” “continue,” or the negative of these terms or other     comparable  <font color="blue">terminology</font></td>
    </tr>
    <tr>
      <td>You  should  not  place  undue  reliance  on     forward-looking statements since they <font color="blue">involve known</font> and <font color="blue">unknown risks</font>,     <font color="blue">uncertainties</font> and other <font color="blue">factors which</font> are, in some cases, beyond our control     and  <font color="blue">which could</font> <font color="blue">materially</font> affect actual results, levels of activity,     performance or <font color="blue">achievements</font></td>
    </tr>
    <tr>
      <td>Factors that may cause actual results to differ     <font color="blue">materially</font> from current expectations, which we describe in more detail in     this section titled “Risks,” include, but are not limited to:       •   unfavorable results of our <font color="blue"><font color="blue">product candidate</font> <font color="blue">development</font> efforts</font>;         •   unfavorable results of our pre-clinical or <font color="blue">clinical testing</font>;         •   delays in obtaining, or failure to obtain FDA approvals;         •   <font color="blue">increased regulation by</font> the FDA and other agencies;         •   the <font color="blue">introduction</font> of <font color="blue"><font color="blue">competitive product</font>s</font>;         •   <font color="blue">impairment</font> of license, patent or other <font color="blue"><font color="blue">proprietary</font> rights</font>;         •   failure to achieve <font color="blue">market <font color="blue">acceptance</font></font> of our products;         •   the impact of present and <font color="blue">future collaborative <font color="blue"><font color="blue">agreement</font>s</font></font>; and         •   failure to <font color="blue">successfully</font> implement our <font color="blue">drug <font color="blue">development</font> strategy</font></td>
    </tr>
    <tr>
      <td>If one or more of these or other risks or <font color="blue">uncertainties</font> materialize, or     if our <font color="blue">underlying <font color="blue">assumptions</font> prove</font> to be incorrect, actual results may vary     <font color="blue"><font color="blue">significant</font>ly from</font> what we projected</td>
    </tr>
    <tr>
      <td>Any forward-looking statement you read     in this <font color="blue">Annual Report </font>on Form 10-K reflects our current views <font color="blue">with respect</font>     to <font color="blue">future events</font> and is subject to these and other risks, <font color="blue">uncertainties</font> and     <font color="blue">assumptions</font> relating to our <font color="blue">operations</font>, results of <font color="blue">operations</font>, business     strategy and liquidity</td>
    </tr>
    <tr>
      <td>We assume <font color="blue">no obligation</font> to <font color="blue">publicly update</font> or revise     these forward-looking statements for any reason, or to update the reasons     actual results could differ <font color="blue">materially</font> from those anticipated in these     forward-looking statements, even if new information <font color="blue">becomes available</font> in the     future</td>
    </tr>
    <tr>
      <td>Risks of our Business       We are a bio<font color="blue">pharmaceutical</font> company with no revenue generating <font color="blue">operations</font> and     <font color="blue">high investment costs</font></td>
    </tr>
    <tr>
      <td>We  expect to <font color="blue">incur losses</font> for a number of years as we expand our     research and <font color="blue">development</font> projects</td>
    </tr>
    <tr>
      <td>There is no assurance that our current     level  of <font color="blue">funds will</font> be sufficient to support all <font color="blue">research expenses</font> to     achieve <font color="blue">commercialization</font> of any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">On November </font>26,     2003, we sold all of our revenue generating <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are now focused     on developing and testing the <font color="blue">product <font color="blue">candidates</font></font> in our <font color="blue">Chrysalin </font>Product     Platform and have allocated most of our resources to bringing these product     <font color="blue">candidates</font> to the market</td>
    </tr>
    <tr>
      <td>However, as described earlier, on <font color="blue">February </font>27,     2006  we acquired the rights to AZX100, and we also intend to continue     preclinical <font color="blue">activities</font> on AZX100 in 2006</td>
    </tr>
    <tr>
      <td>We may invest in other peptide or     small  molecule-based  <font color="blue">therapeutics</font> in the future, but there can be no     assurance that <font color="blue">opportunities</font> of this nature will occur at acceptable terms,     <font color="blue">conditions</font> or timing</td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">no <font color="blue"><font color="blue">pharmaceutical</font> products</font></font> being     sold  or  ready for sale and do not expect to be able to introduce any     <font color="blue"><font color="blue">pharmaceutical</font> products</font> for <font color="blue">at least several years</font></td>
    </tr>
    <tr>
      <td>As a result of our     <font color="blue">significant</font> research and <font color="blue">development</font>, clinical <font color="blue">development</font>, <font color="blue">regulatory</font>     compliance and general and <font color="blue">administrative</font> expenses and the lack of any     products to <font color="blue">generate revenue</font>, we expect to <font color="blue">incur losses</font> for at least the     <font color="blue">next several years</font> and expect that our <font color="blue">losses will increase as</font> we expand our     research and <font color="blue">development</font> <font color="blue">activities</font> and incur <font color="blue">significant</font> expenses for     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Our cash reserves, including the cash received from the     sale of our <font color="blue">bone growth stimulation</font> device business in November 2003, are     the <font color="blue">primary source</font> of our working                                         14       _________________________________________________________________    [47]Table of <font color="blue">Contents       </font>capital</td>
    </tr>
    <tr>
      <td>There  can  be  no assurance that our <font color="blue">cash resources will</font> be     sufficient to cover our future operating <font color="blue">requirements</font>, or <font color="blue">should there</font> be a     need,  other  sources  of  cash will be available, or if available, at     acceptable terms</td>
    </tr>
    <tr>
      <td>We do not expect to receive any <font color="blue">revenue from product sales until</font> we     receive <font color="blue">regulatory</font> approval and begin <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> when that will occur or if it will occur</td>
    </tr>
    <tr>
      <td>We caution that our <font color="blue">future <font color="blue">cash expenditure levels</font></font> are <font color="blue">difficult</font> to     forecast because the forecast is <font color="blue">based on</font> <font color="blue">assumptions</font> about the number of     research projects we pursue, the <font color="blue">pace at which</font> we pursue them, the quality     of the data collected and the requests of the FDA to expand, narrow or     conduct <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> and analyze data</td>
    </tr>
    <tr>
      <td>Changes in any of these     <font color="blue">assumptions</font> can change <font color="blue">significant</font>ly our estimated <font color="blue">cash expenditure levels</font></td>
    </tr>
    <tr>
      <td>However, absent any unforeseen changes to our current business plans, we     intend to maintain <font color="blue">annual expenditure levels within</font> the dlra32 — dlra40 million     range</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> are in <font color="blue">various stages</font> of <font color="blue">development</font> and may not be     <font color="blue">successfully</font> developed or <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, we will not be able     to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>Our product     <font color="blue">candidates</font> are at the <font color="blue">following stages</font> of <font color="blue">development</font>:             •   Acceleration of Fracture Repair       Phase 3 human <font color="blue"><font color="blue">clinical trial</font>s</font>             •   Diabetic Foot Ulcer Healing           Phase 1/2 human <font color="blue"><font color="blue">clinical trial</font>s</font>             •   Spine Fusion                          Phase 1/2 human <font color="blue"><font color="blue">clinical trial</font>s</font>             •   Cartilage Defect Repair               Late stage pre-<font color="blue"><font color="blue">clinical trial</font>s</font>             •   Tendon Repair                         Early stage pre-<font color="blue"><font color="blue">clinical trial</font>s</font>             •   Cardiovascular Repair                 Pre-<font color="blue"><font color="blue">clinical trial</font>s</font>             •   Dental Bone Repair                    Pre-<font color="blue"><font color="blue">clinical trial</font>s</font>            We are subject to the risk that:       •   the FDA finds some or all of our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">in<font color="blue">effective</font></font> or     unsafe;         •   we do not receive <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals;         •   we are unable to get some or all of our <font color="blue">product <font color="blue">candidates</font></font> to market     in a <font color="blue">timely manner</font>;          •   we are not able to produce our <font color="blue">product <font color="blue">candidates</font></font> in commercial     <font color="blue">quantities at reasonable costs</font>;         •   our products undergo post-market evaluations resulting in marketing     <font color="blue">restrictions</font> or withdrawal of our products; or         •   the patients, insurance and/or physician community does not accept our     products</td>
    </tr>
    <tr>
      <td>In  addition,  our product <font color="blue">development</font> programs may be curtailed,     redirected or <font color="blue">eliminated at</font> any time for many reasons, including:       •   adverse or <font color="blue">ambiguous</font> results;         •   undesirable side <font color="blue">effects which delay</font> or extend the trials;         •   <font color="blue">inability</font> to locate, recruit, qualify and retain a sufficient number     of patients for our trials;         •   <font color="blue">regulatory</font> delays or other <font color="blue">regulatory</font> actions;         •   <font color="blue">difficult</font>ies in obtaining <font color="blue">sufficient quantities</font> of the particular     product  candidate or any other <font color="blue">components</font> needed for our pre-clinical     testing or <font color="blue"><font color="blue">clinical trial</font>s</font>;         •   change in the focus of our <font color="blue">development</font> efforts; and         •   re-evaluation of our clinical <font color="blue">development</font> strategy</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [48]Table of <font color="blue">Contents       </font>     We  cannot  predict  whether  we  will  <font color="blue">successfully</font>  develop and     <font color="blue">commercialize</font> any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If we fail to do so, we will     not be able to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>The majority of our <font color="blue">product <font color="blue">candidates</font></font> are all <font color="blue">based on</font> the <font color="blue">same chemical</font>     peptide, Chrysalin</td>
    </tr>
    <tr>
      <td>If one of our <font color="blue">Chrysalin </font><font color="blue">product <font color="blue">candidates</font></font> reveals     safety or <font color="blue">fundamental inefficacy issues</font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, it <font color="blue">could impact</font>     the <font color="blue">development</font> path for all our other current <font color="blue">Chrysalin </font><font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of each of our <font color="blue">product <font color="blue">candidates</font></font> in the <font color="blue">Chrysalin </font>    Product Platform is <font color="blue">based on</font> our knowledge and understanding of how the     <font color="blue">human thrombin</font> molecule <font color="blue">contributes</font> to the repair of <font color="blue">soft tissue</font> and bone</td>
    </tr>
    <tr>
      <td>While there are <font color="blue">important differences</font> in each of the <font color="blue">product <font color="blue">candidates</font></font> in     terms of their purpose (<font color="blue">fracture repair</font>, diabetic foot ulcer, etc), each     <font color="blue">product candidate</font> is <font color="blue">focused on accelerating</font> the repair of <font color="blue">soft tissue</font> and     bone and is <font color="blue">based on</font> the ability of <font color="blue">Chrysalin </font>to mimic specific <font color="blue">attributes</font>     of the <font color="blue">human thrombin</font> molecule to stimulate the body’s natural healing     processes</td>
    </tr>
    <tr>
      <td>Since we are developing the <font color="blue">product <font color="blue">candidates</font></font> in the <font color="blue">Chrysalin </font>Product     Platform in parallel, we expect to learn from the results of each trial and     apply  some  of  our  findings to the <font color="blue">development</font> of the other product     <font color="blue">candidates</font> in the platform</td>
    </tr>
    <tr>
      <td>If one of the <font color="blue">product <font color="blue">candidates</font></font> has negative     <font color="blue">clinical trial</font> results or is shown to be <font color="blue">in<font color="blue">effective</font></font>, it <font color="blue">could impact</font> the     <font color="blue">development</font> path or future <font color="blue">development</font> of the other <font color="blue">product <font color="blue">candidates</font></font> in     the  platform</td>
    </tr>
    <tr>
      <td>If  we  find that one of the <font color="blue">bio<font color="blue">pharmaceutical</font> product</font>     <font color="blue">candidates</font> is unsafe, it <font color="blue">could impact</font> the <font color="blue">development</font> of our other product     <font color="blue">candidates</font> in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot protect</font> the <font color="blue">Chrysalin </font>patent or our <font color="blue">intellectual property</font>     <font color="blue">generally</font>, our ability to develop and <font color="blue">commercialize</font> our <font color="blue">Chrysalin </font>products     will be severely limited</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to maintain and enforce     <font color="blue">patent protection</font> for <font color="blue">Chrysalin </font>and each product resulting from Chrysalin</td>
    </tr>
    <tr>
      <td><font color="blue">Without  </font>patent  protection, other <font color="blue">companies could offer substantially</font>     identical  products  for <font color="blue">sale without incurring</font> the sizable <font color="blue">discovery</font>,     <font color="blue">development</font>  and <font color="blue">licensing costs</font> that we have incurred</td>
    </tr>
    <tr>
      <td>Our ability to     recover these <font color="blue">expenditures</font> and realize <font color="blue">profits upon</font> the sale of products     would then be diminished</td>
    </tr>
    <tr>
      <td><font color="blue">Chrysalin </font>is patented and there have <font color="blue">been no successful challenges</font> to     the <font color="blue">Chrysalin </font>patent</td>
    </tr>
    <tr>
      <td>However, if there were to be a challenge to the patent     or any of the patents for <font color="blue">product <font color="blue">candidates</font></font>, a court may determine that the     patents are invalid or unenforceable</td>
    </tr>
    <tr>
      <td>Even if the validity or <font color="blue">enforceability</font>     of  a  patent  is  upheld  by a court, a court may not prevent alleged     <font color="blue"><font color="blue">infringement</font> on</font> the grounds that <font color="blue">such activity</font> is not <font color="blue">covered by</font> the patent     claims</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font>, whether to enforce our rights to use our or our     <font color="blue">licensors</font>’ patents or to <font color="blue">defend against allegations</font> that we <font color="blue">infringe third</font>     party rights, will be costly, time consuming, and <font color="blue">may distract <font color="blue">management</font></font>     from other <font color="blue">important tasks</font></td>
    </tr>
    <tr>
      <td>As is commonplace in the <font color="blue">biotechnology</font> and <font color="blue">pharmaceutical</font> industry, we     <font color="blue">employ individuals</font> who were <font color="blue">previously employed at</font> other <font color="blue">biotechnology</font> or     <font color="blue">pharmaceutical</font>  companies,  including  our  <font color="blue"><font color="blue">competitor</font>s</font>  or  potential     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>To the extent our employees are involved in research areas     which are similar to those areas in which they were involved at their former     employers, we may be subject to claims that such employees and/or we have     <font color="blue">inadvertently</font> or otherwise used or disclosed the alleged <font color="blue">trade secrets</font> or     other <font color="blue">proprietary</font> information of the <font color="blue">former employers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be     <font color="blue">necessary</font> to <font color="blue">defend against such</font> claims, <font color="blue">which could</font> result in substantial     costs and be a <font color="blue">distraction</font> to <font color="blue">management</font> and which may have a material     adverse effect on us, even if we are successful in <font color="blue">defending such</font> claims</td>
    </tr>
    <tr>
      <td>We also rely in our business on <font color="blue">trade secrets</font>, know-how and other     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Nonetheless, we <font color="blue">cannot assure</font> that those <font color="blue"><font color="blue">agreement</font>s</font>     <font color="blue">will provide adequate protection</font> for our <font color="blue">trade secrets</font>, know-how or other     <font color="blue">proprietary</font> information and prevent their <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>To     the extent that <font color="blue">consultants</font>, key employees or other <font color="blue">third parties apply</font>     <font color="blue">technological</font> information <font color="blue">in<font color="blue">dependent</font>ly</font> developed by them or by others to     our <font color="blue">proposed products</font>,                                         16       _________________________________________________________________    [49]Table of <font color="blue">Contents       </font><font color="blue">disputes may</font> arise as to the <font color="blue"><font color="blue">proprietary</font> rights</font> to such information, which     may not be resolved in our favor</td>
    </tr>
    <tr>
      <td>The risk that other <font color="blue"><font color="blue">parties may</font> breach</font>     <font color="blue">confidentiality</font>  <font color="blue"><font color="blue">agreement</font>s</font>  or that our <font color="blue">trade secrets</font> become known or     <font color="blue">in<font color="blue">dependent</font>ly</font>  dis<font color="blue">covered by</font> <font color="blue"><font color="blue">competitor</font>s</font>, could <font color="blue">adversely</font> affect us by     enabling our <font color="blue"><font color="blue">competitor</font>s</font>, who may have greater experience and financial     resources,  to  copy  or  use  our <font color="blue">trade secrets</font> and other <font color="blue">proprietary</font>     information in the <font color="blue">advancement</font> of their products, methods or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our  success  <font color="blue">also depends on</font> our ability to operate and <font color="blue">commercialize</font>     <font color="blue">products without infringing on</font> the patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that we or our <font color="blue">licensors</font> or suppliers are     infringing  their  patents  or  are <font color="blue">misappropriating</font> their <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>In the event of a successful claim <font color="blue">against us</font> or our <font color="blue">licensors</font>     or  suppliers for <font color="blue">infringement</font> of the patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of     others, we may be required to, among other things:       •   pay substantial damages;         •   stop using our <font color="blue">technologies</font>;         •   <font color="blue">stop certain research</font> and <font color="blue">development</font> efforts;         •   develop non-infringing products or methods; and         •   obtain one or more <font color="blue">licenses from third parties</font></td>
    </tr>
    <tr>
      <td>A license required under any <font color="blue">such patents</font> or <font color="blue"><font color="blue">proprietary</font> rights</font> may not     be available to us, or may not be <font color="blue">available on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>If we or     our <font color="blue">licensors</font> or suppliers are sued for <font color="blue">infringement</font>, we <font color="blue">could encounter</font>     substantial delays in, or be <font color="blue">prohibited from</font>, developing, <font color="blue">manufacturing</font> and     <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">product <font color="blue">candidates</font></font> are in early stages of <font color="blue">development</font> and may     never be <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>Research, <font color="blue">development</font> and pre-<font color="blue">clinical testing</font> are long, expensive and     <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">than <font color="blue"><font color="blue">indication</font>s</font></font> for <font color="blue">fracture repair</font> and diabetic     ulcer healing, none of our other <font color="blue">Chrysalin </font><font color="blue">product <font color="blue">candidates</font></font> has reached     <font color="blue">clinical trial</font> testing</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font> of <font color="blue">Chrysalin </font>for the repair of     cartilage  defects,  tendons and <font color="blue">cardiovascular repair</font> is currently in     pre-<font color="blue">clinical testing</font> or the <font color="blue">research stage</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success depends</font>, in     part, on our ability to complete pre-clinical <font color="blue">development</font> of these and other     <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">advance them</font> to the <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in advancing our early stage <font color="blue">product <font color="blue">candidates</font></font>     into <font color="blue">clinical testing</font> for any reason, our business <font color="blue">prospects will</font> be harmed</td>
    </tr>
    <tr>
      <td>Acquisition of New Class of Molecules, ICARMs™          On <font color="blue">February </font>23, 2006 the Company <font color="blue">entered into</font> an <font color="blue">agreement</font> to purchase     <font color="blue">certain assets</font> and assume <font color="blue">certain liabilities</font> of AzERx, Inc</td>
    </tr>
    <tr>
      <td>for dlra390cmam000 in     cash and the issuance of 1cmam355cmam000 shares of the Company’s <font color="blue">common stock</font>,     with a <font color="blue">market value</font> of dlra7dtta7 million determined by the closing share price on     the date the <font color="blue">agreement</font> was <font color="blue">entered into</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">transaction</font> was completed     (closed) on  <font color="blue">February </font>27,  2006</td>
    </tr>
    <tr>
      <td>Under  the terms of the <font color="blue">transaction</font>,     OrthoLogic acquired an <font color="blue">exclusive license</font> for the core <font color="blue">intellectual property</font>     relating to AZX100, and will continue to develop the new class of compounds     in the field of <font color="blue">smooth muscle relaxation called</font> Intracellular Actin Relaxing     Molecules, or ICARMs™, <font color="blue">based on</font> the <font color="blue">unique technology</font> developed by AzERx</td>
    </tr>
    <tr>
      <td>The <font color="blue">acquisition provides</font> the Company with a <font color="blue">new technology platform</font> that     <font color="blue">diversifies</font> the portfolio, and may provide more <font color="blue">than one potential product</font></td>
    </tr>
    <tr>
      <td>AZX100 is     currently  being <font color="blue">investigated</font> for <font color="blue">medically important</font> and <font color="blue">commercially</font>     <font color="blue">significant</font> applications such as the treatment of <font color="blue">vasospasm associated with</font>     subarachnoid hemorrhage, prevention of <font color="blue">keloid scarring</font>, and the treatment of     asthma</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>and human in vitro studies have shown that this novel     compound has the ability to relax smooth muscle in multiple tissue types</td>
    </tr>
    <tr>
      <td><font color="blue">While the Company </font>performed a <font color="blue">reasonable level</font> of <font color="blue">due diligence on</font> AZX100     and the rights acquired, there can be <font color="blue">no assurances</font> that the Company will     recover the costs of its <font color="blue">investment from</font> the future <font color="blue">development</font> of AZX100</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [50]Table of <font color="blue">Contents       </font>The loss of our key <font color="blue">management</font> and <font color="blue">scientific personnel may hinder</font> our     ability to execute our business plan</td>
    </tr>
    <tr>
      <td>As a small company our success depends on the continuing <font color="blue">contributions</font>     of  our  <font color="blue">management</font>  team  and  scientific  personnel, and maintaining     <font color="blue">relationships</font> with the network of medical and academic centers in the United     States that conduct our <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">resignation</font> or retirement of     senior <font color="blue">management</font> is a <font color="blue">current risk</font> that could <font color="blue">materially</font> negatively affect     our business prospects</td>
    </tr>
    <tr>
      <td>Reliance on Outside Suppliers and Consultants          We <font color="blue">rely on outside suppliers</font> and <font color="blue">consultants</font> for the <font color="blue">manufacture</font> of     <font color="blue">Chrysalin </font> and  AZX100  and  technical  assistance in our research and     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> of our suppliers to meet our production     quality <font color="blue">requirements</font> in a <font color="blue">timely manner</font>, or the lack of <font color="blue">availability</font> of     experienced <font color="blue">consultants</font> to assist in our research and <font color="blue">development</font> efforts,     could have a material effect on our ability to perform research or clinical     trials</td>
    </tr>
    <tr>
      <td>We face an inherent risk of <font color="blue">liability</font> in the event that the use or misuse of     our products results in <font color="blue">personal injury</font> or death</td>
    </tr>
    <tr>
      <td>The use of our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue"><font color="blue">clinical trial</font>s</font>, and the sale of     any approved products, may expose us to product <font color="blue">liability</font> claims, which     could result in <font color="blue">financial losses</font></td>
    </tr>
    <tr>
      <td>Our clinical <font color="blue">liability</font> insurance coverage     may  not be sufficient to cover claims that may be made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>In     addition, we may not be able to maintain <font color="blue">insurance coverage at</font> a reasonable     cost or in <font color="blue">sufficient amounts</font> or scope to <font color="blue">protect us against losses</font></td>
    </tr>
    <tr>
      <td>Any     claims  <font color="blue">against us</font>, regardless of their merit, could severely harm our     <font color="blue">financial condition</font>, strain our <font color="blue">management</font> and other resources and <font color="blue">adversely</font>     impact or eliminate the prospects for <font color="blue">commercialization</font> of the <font color="blue">product which</font>     is the subject of any such claim</td>
    </tr>
    <tr>
      <td><font color="blue">Additional  </font>authorized  shares of our <font color="blue">common stock</font> and <font color="blue">preferred stock</font>     available for <font color="blue">issuance may</font> have dilutive, anti-takeover and other material     <font color="blue">effects on</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We are authorized to issue 100cmam000cmam000 shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, there were 38cmam124cmam742 shares of <font color="blue">common stock</font> issued and     outstanding</td>
    </tr>
    <tr>
      <td>However, the total number of shares of our <font color="blue">common stock</font> issued     and outstanding does not include shares reserved in <font color="blue">anticipation</font> of the     exercise  of  options, warrants or <font color="blue">additional</font> investment rights</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31,  2005,  we  had  stock  options  outstanding  to purchase     approximately 3cmam040cmam785 shares of our <font color="blue">common stock</font>, the <font color="blue">exercise price</font> of     which  range  between dlra2dtta43 per share to dlra17dtta38 per share, and we have     <font color="blue">reserved shares</font> of our <font color="blue">common stock</font> for issuance in <font color="blue">connection with</font> the     <font color="blue">potential exercise thereof</font></td>
    </tr>
    <tr>
      <td>In addition,     in  the  event that any future financing or <font color="blue">consideration</font> for a future     <font color="blue">acquisition should</font> be in the form of, be <font color="blue">convertible into</font> or exchangeable     for, equity securities, investors will experience <font color="blue">additional</font> dilution</td>
    </tr>
    <tr>
      <td>We also have 2cmam000cmam000 shares of authorized <font color="blue">preferred stock</font>, the terms     of which may be fixed by our Board</td>
    </tr>
    <tr>
      <td>We presently have <font color="blue">no outstanding shares</font>     of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>While we have no present plans to issue any <font color="blue">additional</font>     shares of <font color="blue">preferred stock</font>, our Board has the authority, without stockholder     approval, to create and issue one or more series of such <font color="blue">preferred stock</font> and     to  determine the voting, dividend and other rights of holders of such     <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>The issuance of any of such series of <font color="blue">preferred stock</font> may     have an adverse effect on the holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> the <font color="blue">Rights Agreement </font>dated as of March 4, 1997     between  the Company and the Bank of New York, as amended (the “Rights     Agreement”),  our  <font color="blue">board approved</font> the <font color="blue">designation</font> of 500cmam000 shares of     <font color="blue">Series A Preferred Stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">Rights Agreement </font>and the exercise of rights to     purchase <font color="blue">Series A Preferred Stock</font> pursuant to the terms thereof may delay,     defer  or  prevent a change in control because the terms of any issued     <font color="blue">Series A Preferred Stock</font> <font color="blue">would potentially prohibit</font> our <font color="blue">consummation</font> of     certain extraordinary corporate <font color="blue">transaction</font>s without the approval of the     Board</td>
    </tr>
    <tr>
      <td>In addition to the anti-takeover effects of the <font color="blue">rights granted under</font>     the Rights Agreement, the issuance of <font color="blue">preferred stock</font>, <font color="blue">generally</font>, could have     a dilutive effect on our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [51]Table of <font color="blue">Contents       </font>Our stock price is volatile and <font color="blue">fluctuates due</font> to a variety of factors</td>
    </tr>
    <tr>
      <td>Our stock price has varied <font color="blue">significant</font>ly in the past (from a low of     dlra2dtta93 to a high of dlra8dtta96 from January 1, 2004 to <font color="blue">December </font>31, 2005) and may     vary in the future due to a number of factors, including:       •   <font color="blue">announcement</font> of the results of, or delays in, preclinical and clinical     studies;         •   <font color="blue">fluctuations</font> in our operating results;         •   <font color="blue">development</font>s in <font color="blue">litigation</font> to which we or a <font color="blue">competitor</font> is subject;         •   <font color="blue">announcement</font>s and timing of potential acquisitions, divestitures,     capital raising <font color="blue">activities</font> and <font color="blue">conversions</font> of <font color="blue">preferred stock</font>;         •   <font color="blue">announcement</font>s of <font color="blue">technological</font> innovations or <font color="blue">new products by us</font> or     our <font color="blue"><font color="blue">competitor</font>s</font>;         •   FDA and other <font color="blue">regulatory</font> actions;          •   <font color="blue">development</font>s <font color="blue">with respect</font> to our or our <font color="blue"><font color="blue">competitor</font>s</font>’ patents or     <font color="blue"><font color="blue">proprietary</font> rights</font>;         •   public concern as to the safety of products developed by us or others;     and         •   changes in <font color="blue"><font color="blue">stock market</font> analyst recommendations</font> regarding us, other     drug <font color="blue">development</font> companies or the <font color="blue">pharmaceutical</font> industry <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has from time to time experienced <font color="blue">significant</font>     price  and  volume  <font color="blue">fluctuations</font>  that  are unrelated to the operating     performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may     <font color="blue">adversely</font> affect the <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>Our <font color="blue">Chrysalin </font>Product Platform is currently in the <font color="blue">human testing phase</font>     for <font color="blue">three <font color="blue">potential products</font></font> and earlier pre-<font color="blue">clinical testing</font> phases for two     other <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>The FDA and comparable agencies in many foreign     countries  impose  substantial  <font color="blue">limitations</font> on the <font color="blue">introduction</font> of new     <font color="blue">pharmaceutical</font>s through costly and time-consuming <font color="blue">laboratory</font> and clinical     testing  and  other procedures</td>
    </tr>
    <tr>
      <td>The process of obtaining FDA and other     required  <font color="blue">regulatory</font>  approvals  is  lengthy, expensive and uncertain</td>
    </tr>
    <tr>
      <td>Chrysalin, as a new drug, is subject to the <font color="blue">most stringent level</font> of FDA     review</td>
    </tr>
    <tr>
      <td>Even after we have invested substantial funds in the <font color="blue">development</font> of our     three <font color="blue">Chrysalin </font>products and even if the results of our <font color="blue">current clinical</font>     trials are favorable, there can be no guarantee that the FDA will grant     approval of <font color="blue">Chrysalin </font>for the <font color="blue">indicated uses</font> or that it will do so in a     <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">successfully</font> bring one or more products to market, there is no     assurance that we will be able to <font color="blue">successfully</font> <font color="blue">manufacture</font> or market the     products  or that <font color="blue">potential customers will buy them</font> if, for example, a     <font color="blue">competitive product</font> has <font color="blue">greater efficacy</font> or is deemed more <font color="blue">cost <font color="blue">effective</font></font></td>
    </tr>
    <tr>
      <td>In addition, the market in which we will sell any <font color="blue">such products</font> is dominated     by a number of large <font color="blue">corporations</font> that have <font color="blue">vastly greater resources than</font> we     have, <font color="blue">which may impact</font> our ability to <font color="blue">successfully</font> market our products or     maintain any <font color="blue">technological</font> advantage we might develop</td>
    </tr>
    <tr>
      <td>We also would be     subject to changes in                                         19       _________________________________________________________________    [52]Table of <font color="blue">Contents       </font><font color="blue"><font color="blue">regulations</font> governing</font> the <font color="blue">manufacture</font> and marketing of our products, which     <font color="blue">could increase</font> our costs, reduce any <font color="blue">competitive advantage</font> we may have     and/or <font color="blue">adversely</font> affect our <font color="blue">marketing <font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>The results of our late stage <font color="blue"><font color="blue">clinical trial</font>s</font> may be insufficient to obtain     FDA approval, <font color="blue">which could</font> result in a substantial delay in our ability to     <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>Positive results from pre-clinical studies and early <font color="blue"><font color="blue">clinical trial</font>s</font> do     not ensure positive results in more advanced <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>If we are     unable to <font color="blue">demonstrate</font> that a <font color="blue">product candidate</font> will be safe and <font color="blue">effective</font> in     advanced <font color="blue"><font color="blue">clinical trial</font>s</font> involving larger numbers of patients, we will be     unable to submit the NDA <font color="blue">necessary</font> to receive <font color="blue">approval from</font> the FDA to     <font color="blue">commercialize</font> that product</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently conducting</font> a Phase 2b and Phase 3 human <font color="blue">clinical trial</font>     on <font color="blue">Chrysalin </font>for <font color="blue">fracture repair</font> <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to achieve the     <font color="blue">primary endpoints</font> in these <font color="blue"><font color="blue">clinical trial</font>s</font> or the results are <font color="blue">ambiguous</font>, we     will have to determine whether to redesign our <font color="blue">Chrysalin </font><font color="blue">fracture repair</font>     <font color="blue">product candidate</font> and our protocols and continue with <font color="blue">additional</font> testing, or     cease <font color="blue">activities</font> in this area</td>
    </tr>
    <tr>
      <td><font color="blue">Redesigning </font>the <font color="blue">product candidate</font> could be     extremely costly and time-consuming</td>
    </tr>
    <tr>
      <td>A substantial delay in obtaining FDA     approval or <font color="blue">termination</font> of the <font color="blue">Chrysalin </font><font color="blue">fracture repair</font> <font color="blue">product candidate</font>     could result in a delay in our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>Patients <font color="blue">may discontinue</font> their <font color="blue">participation</font> in our clinical studies, which     <font color="blue">may negatively impact</font> the results of these studies and extend the timeline     for <font color="blue">completion</font> of our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>As with all <font color="blue"><font color="blue">clinical trial</font>s</font>, we are subject to the risk that patients     enrolled in our clinical studies <font color="blue">may discontinue</font> their <font color="blue">participation</font> at any     time  during  the study as a result of a number of factors, including,     withdrawing their consent or experiencing adverse clinical events, which may     or may not be judged related to our <font color="blue">product <font color="blue">candidates</font></font> under evaluation</td>
    </tr>
    <tr>
      <td>We     are subject to the risk that if a large number of patients in any one of our     <font color="blue">studies discontinue</font> their <font color="blue">participation</font> in the study, the results from that     study may not be positive or may not support an NDA for <font color="blue">regulatory</font> approval     of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, the time required to complete <font color="blue"><font color="blue">clinical trial</font>s</font> is <font color="blue">dependent</font>     upon,  among  other  factors,  the rate of <font color="blue">patient <font color="blue">enrollment</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Patient     </font><font color="blue">enrollment</font> is a function of many factors, including:       •   the size of the <font color="blue">patient population</font>;         •   the nature of the clinical protocol <font color="blue">requirements</font>;         •   the diversion of patients to other trials or <font color="blue">marketed therapies</font>;         •   our ability to recruit and <font color="blue">manage clinical centers</font> and associated     trials;         •   the proximity of patients to <font color="blue">clinical sites</font>; and         •   the <font color="blue">patient eligibility criteria</font> for the study</td>
    </tr>
    <tr>
      <td>Even  if we obtain <font color="blue">marketing approval</font>, our products will be subject to     ongoing <font color="blue">regulatory</font> oversight, which may affect our ability to <font color="blue">successfully</font>     <font color="blue">commercialize</font> any products we may develop</td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue">regulatory</font> approval of a <font color="blue">product candidate</font>, the     <font color="blue">approval may</font> be subject to <font color="blue">limitations</font> on the <font color="blue">indicated uses</font> for which the     product is marketed or require costly post-marketing follow-up studies</td>
    </tr>
    <tr>
      <td>After we obtain <font color="blue">marketing approval</font> for any product, the <font color="blue">manufacture</font>r and the     <font color="blue">manufacturing</font> facilities for that <font color="blue">product will</font> be subject to continual     review and <font color="blue">periodic inspections by</font> the FDA and other <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>The subsequent <font color="blue">discovery</font> of <font color="blue">previously unknown problems with</font> the product, or     with the <font color="blue">manufacture</font>r or facility, may result in <font color="blue">restrictions</font> on the product     or <font color="blue">manufacture</font>r, including withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [53]Table of <font color="blue">Contents       </font>     If we fail to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, we may be     subject to fines, suspension or withdrawal of <font color="blue">regulatory</font> approvals, product     recalls,  seizure  of  products,  operating  <font color="blue">restrictions</font> and criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> may not gain <font color="blue">market <font color="blue">acceptance</font></font> among physicians,     patients and the <font color="blue">medical community</font>, including <font color="blue">insurance companies</font> and other     third  party  payors</td>
    </tr>
    <tr>
      <td>If our <font color="blue">product <font color="blue">candidates</font></font> fail to achieve market     <font color="blue">acceptance</font>, our ability to <font color="blue">generate revenue</font> will be limited</td>
    </tr>
    <tr>
      <td>Even  if  we  obtain <font color="blue">regulatory</font> approval for our products, market     <font color="blue">acceptance</font> will depend on our ability to <font color="blue">demonstrate</font> to physicians and     patients the benefits of our products in terms of safety, efficacy, and     convenience, ease of <font color="blue">administration</font> and <font color="blue">cost <font color="blue">effective</font></font>ness</td>
    </tr>
    <tr>
      <td>In addition, we     believe <font color="blue">market <font color="blue">acceptance</font></font> depends on the <font color="blue">effective</font>ness of our marketing     strategy, the pricing of our products and the <font color="blue">reimbursement policies</font> of     <font color="blue">government</font>  and  third-party  payors</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>may not prescribe our     products, and <font color="blue">patients may</font> determine, for any reason, that our product is     not useful to them</td>
    </tr>
    <tr>
      <td>Insurance companies and other <font color="blue">third <font color="blue">party payors</font> may</font>     determine  not to reimburse for the cost of the therapy</td>
    </tr>
    <tr>
      <td>If any of our     product  <font color="blue">candidates</font> fails to achieve <font color="blue">market <font color="blue">acceptance</font></font>, our ability to     <font color="blue">generate revenue</font> will be limited</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> industry is subject to <font color="blue">stringent regulation</font>, and failure     to  obtain  <font color="blue">regulatory</font>  approval will prevent <font color="blue">commercialization</font> of our     products</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font>, pre-clinical and <font color="blue">clinical trial</font> <font color="blue">activities</font>     and the <font color="blue">manufacture</font> and marketing of any products that we may <font color="blue">successfully</font>     develop are subject to an extensive <font color="blue">regulatory</font> approval process by the FDA     and other <font color="blue">regulatory</font> agencies in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>The process     of obtaining required <font color="blue">regulatory</font> approvals for drugs is lengthy, expensive     and uncertain, and any such <font color="blue">regulatory</font> approvals may entail <font color="blue">limitations</font> on     the <font color="blue">indicated usage</font> of a drug, which may reduce the drug’s market potential</td>
    </tr>
    <tr>
      <td>In order to obtain FDA approval to <font color="blue">commercialize</font> any <font color="blue">product candidate</font>,     an NDA must be submitted to the FDA demonstrating, among other things, that     the <font color="blue">product candidate</font> is safe and <font color="blue">effective</font> for use in humans for each     <font color="blue">target <font color="blue">indication</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">regulatory</font> <font color="blue">submissions</font> may be delayed, or we may     cancel plans to make <font color="blue">submissions</font> for <font color="blue">product <font color="blue">candidates</font></font> for a number of     reasons, including:       •   negative or <font color="blue">ambiguous</font> pre-clinical or <font color="blue">clinical trial</font> results;         •   changes in <font color="blue">regulations</font> or the adoption of new <font color="blue">regulations</font>;         •   unexpected <font color="blue">technological</font> <font color="blue">development</font>s; and         •   <font color="blue">development</font>s by our <font color="blue"><font color="blue">competitor</font>s</font> that are more <font color="blue">effective</font> than our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Consequently, we <font color="blue">cannot assure</font> that we will make our <font color="blue">submissions</font> to the     FDA  in  the  timeframe  that  we have planned, or at all, or that our     <font color="blue">submissions</font> will be <font color="blue">approved by</font> <font color="blue">the FDA Even </font>if <font color="blue">regulatory</font> clearance is     obtained, post-market evaluation of our products, if required, could result     in <font color="blue">restrictions</font> on a product’s marketing or withdrawal of a <font color="blue">product from</font> the     <font color="blue">market as well as possible civil</font> and <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td>Clinical trials are subject to <font color="blue">oversight by institutional review boards</font>     and the FDA to ensure compliance with the FDA’s good <font color="blue">clinical practice</font>     <font color="blue">regulations</font>, as well as other <font color="blue">requirements</font> for good <font color="blue">clinical practice</font>s</td>
    </tr>
    <tr>
      <td>We     depend, in part, on third-party laboratories and <font color="blue">medical institutions</font> to     conduct pre-clinical studies and <font color="blue"><font color="blue">clinical trial</font>s</font> for our products and other     third-party organizations, usually universities, to perform <font color="blue">data collection</font>     and analysis, all of <font color="blue">which must</font> maintain both good <font color="blue">laboratory</font> and good     <font color="blue">clinical practice</font>s</td>
    </tr>
    <tr>
      <td>If any such standards are not complied with in our     <font color="blue"><font color="blue">clinical trial</font>s</font>, the FDA may suspend or terminate such trial, which would     <font color="blue">severely delay</font> our <font color="blue">development</font> and possibly end the <font color="blue">development</font> of a product     candidate</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________    [54]Table of <font color="blue">Contents       </font>     We  <font color="blue">also currently</font> and in the <font color="blue">future will depend upon third party</font>     <font color="blue">manufacture</font>rs of our products, which are and will be required to <font color="blue">comply with</font>     the applicable <font color="blue">FDA Good Manufacturing Practice </font><font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We cannot be     certain that our present or future <font color="blue">manufacture</font>rs and <font color="blue">suppliers will comply</font>     with these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">comply with</font> these <font color="blue">regulations</font> may     result in <font color="blue">restrictions</font> in the sale of, or withdrawal of the <font color="blue">products from</font>     the market</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">by third parties with</font> these standards and practices     are outside of our <font color="blue">direct control</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to <font color="blue">regulation under</font> state and federal laws,     including <font color="blue">requirements</font> regarding occupational safety, <font color="blue">laboratory</font> practices,     <font color="blue">environmental protection</font> and <font color="blue">hazardous</font> substance control, and may be subject     to other local, state, federal and <font color="blue">foreign regulation</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the     impact of such <font color="blue">regulations</font> on us, although they could impose <font color="blue">significant</font>     <font color="blue">restrictions</font> on our business and require us to incur <font color="blue">additional</font> expenses to     comply</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">competitor</font>s</font> develop and <font color="blue">market products</font> that are more <font color="blue">effective</font> than     ours,  or  obtain  marketing  approval  before  we  do, our commercial     <font color="blue">opportunities</font> will be reduced or eliminated</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">pharmaceutical</font> and <font color="blue">biotechnology</font> industries is     intense  and  is  expected  to  increase</td>
    </tr>
    <tr>
      <td><font color="blue">Several  </font><font color="blue">biotechnology</font>  and     <font color="blue">pharmaceutical</font> companies, as well as academic laboratories, universities and     other  research  institutions, are involved in research and/or product     <font color="blue">development</font> for <font color="blue">various treatments</font> for or involving <font color="blue">fracture repair</font> and     <font color="blue"><font color="blue">diabetic ulcer</font> healing</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">significant</font>ly greater     research and <font color="blue">development</font> <font color="blue">capabilities</font>, experience in obtaining <font color="blue">regulatory</font>     approvals and <font color="blue">manufacturing</font>, marketing, financial and managerial resources     than we have</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently aware</font> of the following <font color="blue">development</font> efforts by     our <font color="blue"><font color="blue">competitor</font>s</font>:       •   Acceleration of Fracture Repair: While there is <font color="blue">currently no product</font>     <font color="blue">approved by</font> the FDA for <font color="blue">acceleration</font> of <font color="blue">fracture repair</font>, at least one large     <font color="blue">pharmaceutical</font> company, Pfizer, Inc, is conducting human <font color="blue"><font color="blue">clinical trial</font>s</font> in     the <font color="blue">United States </font>for this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>•   Diabetic Ulcer Healing: To our knowledge, there are <font color="blue">three corporate</font>     sponsored <font color="blue"><font color="blue">clinical trial</font>s</font> underway on new drug substances for <font color="blue">diabetic ulcer</font>     healing</td>
    </tr>
    <tr>
      <td>These early stage <font color="blue"><font color="blue">clinical trial</font>s</font> are being <font color="blue">conducted by</font> <font color="blue">Genentech     </font>on  <font color="blue">recombinant</font>  human  vascular  <font color="blue">endothelial</font>  growth  factor, by King     Pharmaceuticals  on MRE0094, an <font color="blue">adenosine</font> A2A <font color="blue">receptor agonist</font>, and by     Agennix on topical talactoferrin</td>
    </tr>
    <tr>
      <td>Our  <font color="blue"><font color="blue">competitor</font>s</font> may succeed in developing products that are more     <font color="blue">effective</font>  than  the ones we have under <font color="blue">development</font> or that render our     <font color="blue">proposed products</font> or <font color="blue">technologies</font> noncompetitive or obsolete</td>
    </tr>
    <tr>
      <td>In addition,     certain of such <font color="blue"><font color="blue">competitor</font>s</font> may achieve product <font color="blue">commercialization</font> before we     do</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue"><font color="blue">competitor</font>s</font> develops a product that is more <font color="blue">effective</font> than     one we are developing or plan to develop, or is able to obtain FDA approval     for  <font color="blue">commercialization</font>  before  we  do,  we may not be able to achieve     <font color="blue">significant</font> <font color="blue">market <font color="blue">acceptance</font></font> for <font color="blue">certain products</font> of ours, which would have     a material adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>reform and <font color="blue">restrictions</font> on reimbursements may limit our financial     returns</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our products may depend in     part on the extent to which <font color="blue">government</font> health <font color="blue">administration</font> authorities,     private  health  insurers  and other <font color="blue">third <font color="blue">party payors</font> will reimburse</font>     consumers  for  the  cost  of  these  products</td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payors</font> are     <font color="blue">increasingly</font>  <font color="blue">challenging</font>  both  the need for, and the price of, novel     <font color="blue">therapeutic drugs</font> and <font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement status</font> of     newly approved <font color="blue">therapeutics</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font><font color="blue">third party reimbursement may</font> not be     available  for our <font color="blue">drug products</font> to <font color="blue">enable us</font> to maintain <font color="blue">price levels</font>     sufficient to realize an <font color="blue">appropriate return on</font> our <font color="blue">investments</font> in research     and product <font color="blue">development</font>, <font color="blue">which could</font> restrict our ability to <font color="blue">commercialize</font> a     <font color="blue">particular drug candidate</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [55]Table of <font color="blue">Contents       </font>     We  caution  that  the <font color="blue">foregoing list</font> of <font color="blue">important factors</font> is not     exclusive</td>
    </tr>
    <tr>
      <td>The <font color="blue">foregoing list</font> of     <font color="blue">important factors</font> is not exclusive and may not be up to date</td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>in any of these areas, which are more <font color="blue">fully described</font>     elsewhere in “Item 1 - Business,” and “Item 7 — Management’s Discussion and     Analysis of Financial Condition and Results of Operations” could cause our     results to differ <font color="blue">materially</font> from results that have been or may be projected     by us</td>
    </tr>
  </tbody>
</table>